Fusion Pharmaceuticals Inc.

NasdaqGS:FUSN Stock Report

Market Cap: US$1.8b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Fusion Pharmaceuticals Dividends and Buybacks

Dividend criteria checks 0/6

Fusion Pharmaceuticals does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-7.2%

Buyback Yield

Total Shareholder Yield-7.2%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Seeking Alpha • Mar 03

Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook

Summary Fusion Pharmaceuticals is an oncology company focused on precision medicine and radiopharmaceuticals. The company's clinical candidates show promise in targeting and treating cancers with unmet needs. Fusion has a strong financial position, with enough cash to fund operations until Q2 2025, and strategic partnerships to support its clinical pipeline. Read the full article on Seeking Alpha
Analysis Article • Jan 30

Health Check: How Prudently Does Fusion Pharmaceuticals (NASDAQ:FUSN) Use Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Sep 16

Fusion Pharmaceuticals initiated at buy at Truist on lead candidate for solid tumors

Truist has initiated Fusion Pharmaceuticals (NASDAQ:FUSN) at buy citing the potential of the company's lead candidate, FPI-1434, currently in phase 1 for solid tumors. The firm has a $10 price target (~217% upside based on Thursday's close). Analyst Nicole Germino said that initial phase 1 data for FPI-1434, which targets the cancer biomarker IGF-1R, has been promising, adding that further data in 1H 2023 could bring upside. She sees ~400M in peak sales for FPI-1434. Germino also wrote that the radiopharma company's technology platform, investment in reliable suppliers, and in-house manufacturing help differentiate it from peers. In 2020, Fusion entered into a partnership with AstraZeneca (AZN) for the development of targeted alpha therapies. In late August, Fusion (FUSN) dosed the first patient in a  phase 1/2 study examining FPI-1966 in patients with advanced solid tumors.
Seeking Alpha • Aug 29

Fusion Pharma doses first patient in phase 1/2 study for solid tumors treatment

Fusion Pharmaceuticals (NASDAQ:FUSN) said on Monday the first patient had been dosed in the Phase 1/2 study testing FPI-1966 in patients with advanced solid tumors. The study will evaluate FPI-1966 in patients with solid tumors expressing FGFR3, a validated cancer target found in multiple tumor types, notably bladder, ovarian and head and neck cancers. The study will employ a 3 + 3 dose escalation design to evaluate multiple ascending doses of FPI-1966.
Analysis Article • Aug 10

Will Fusion Pharmaceuticals (NASDAQ:FUSN) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Aug 09

Fusion Pharmaceuticals GAAP EPS of -$0.44 beats by $0.09, revenue of $0.57M beats by $0.46M

Fusion Pharmaceuticals press release (NASDAQ:FUSN): Q2 GAAP EPS of -$0.44 beats by $0.09. Revenue of $0.57M (+9.6% Y/Y) beats by $0.46M.
Seeking Alpha • Jun 23

Fusion Pharma wins FDA nod to start trials for solid tumor candidate

The clinical-stage oncology company Fusion Pharmaceuticals (NASDAQ:FUSN) announced on Thursday that the FDA cleared its Investigational New Drug (IND) applications for [225Ac]-FPI-2059 and the corresponding imaging analogue [111In]-FPI-2058. FPI-2059 is a small molecule designed to deliver actinium-225 to tumor tissue expressing neurotensin receptor 1 (NTSR1), a protein that is excessively detected in multiple solid tumor types. Fusion (FUSN) intends to launch a Phase 1, non-randomized, open-label clinical trial for the candidate targeting patients with solid tumors expressing NTSR1. The trial particpants will undergo a screening process with the administration of FPI-2058, an imaging analogue of FPI-2059. In April 2021, Ipsen (OTCPK:IPSEY) (OTCPK:IPSEF) sold [177Lu]-IPN-1087 (IPN-1087), a lutetium-based beta-emitting radiopharmaceutical to Fusion (FUSN) which later converted it to alpha-emitting [225Ac]-FPI-2059.
Analysis Article • Jan 16

We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Aug 28

We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Apr 05

We're Hopeful That Fusion Pharmaceuticals (NASDAQ:FUSN) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Mar 01

How Much Of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Do Institutions Own?

A look at the shareholders of Fusion Pharmaceuticals Inc. ( NASDAQ:FUSN ) can tell us which group is most powerful...
Analysis Article • Jan 25

Who Has Been Buying Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Shares?

We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...
Analysis Article • Dec 21

Here's Why We're Not Too Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if FUSN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FUSN's dividend payments have been increasing.

Dividend Yield vs Market

Fusion Pharmaceuticals Dividend Yield vs Market
How does FUSN dividend yield compare to the market?
SegmentDividend Yield
Company (FUSN)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.1%
Industry Average (Biotechs)2.2%
Analyst forecast (FUSN) (up to 3 years)n/a

Notable Dividend: Unable to evaluate FUSN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate FUSN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate FUSN's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as FUSN has not reported any payouts.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/06/06 04:56
End of Day Share Price 2024/06/04 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Fusion Pharmaceuticals Inc. is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MartinBloom Burton & Co.
Justin WalshB. Riley Securities, Inc.
Brian Kemp DolliverBrookline Capital Markets